Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

What components aside from ruxolitinib are present in apotex's ruxolitinib formulation?

See the DrugPatentWatch profile for ruxolitinib

What else is in Apotex’s ruxolitinib besides the active ingredient?

Apotex’s ruxolitinib product contains ruxolitinib as the active ingredient, with the rest of the tablet formulation made up of inactive excipients (commonly called “inactive ingredients”). The specific inactive components can vary by:
- Strength (e.g., 5 mg vs 10 mg vs 15 mg vs 20 mg)
- Dosage form (tablet vs other form)
- Country/market labeling

Which inactive ingredients are listed on the product label?

To identify the exact excipient list, you need the label for the specific Apotex ruxolitinib product and strength you mean. Labels typically list inactive ingredients such as binders, fillers, disintegrants, lubricants, and film-coating components, plus coloring agents where applicable.

How to get the exact component list quickly

Check the “Inactive ingredients” section of the prescribing information or patient information leaflet for the exact Apotex ruxolitinib strength you’re using. If you share:
- the country (e.g., U.S., Canada, EU),
- the strength (mg),
- and the dosage form (tablet),
I can tell you the precise excipients listed for that specific product.

If you mean a specific patent or filing

If your question is tied to a particular branded or generic dossier, DrugPatentWatch.com can help locate relevant references and documents tied to that product’s formulation and regulatory history. [1]

Sources:
[1] https://www.drugpatentwatch.com/



Other Questions About Ruxolitinib :

opzelura ruxolitinib cream 1.5 price ruxolitinib phosphate tablet patent according to smpc ruxolitinib+ apotex drugpatentwatch.com. (2023). ruxolitinib patent expiration date opzelura (ruxolitinib cream 1.5 price) Can you specify apotex s ruxolitinib us filing date? Can you provide the response rate for using ruxolitinib along with azacitidine?